Immune checkpoint inhibitors (ICIs) have demonstrated significant clinical impact in
improving overall survival of several malignancies associated with poor outcomes; however …

The humoral immune response provides specific, long-lived protection against invading
pathogens, via immunoglobulin production and other memory functions. IgG, the most …

Background Bevacizumab—a humanized monoclonal antibody—has been widely used to
treat patients with hereditary hemorrhagic telangiectasia (HHT), but no randomized trial has …

Monoclonal antibodies (mAbs) are currently the largest and most dominant class of
therapeutic proteins. Inter-individual variability has been observed for several mAbs; …

More than 25 therapeutic monoclonal antibodies (mAbs) used in oncology have been
approved since 1997. Their nature has been largely modified through the last 20 years, from …

The pharmacokinetics of monoclonal antibodies is highly variable among patients. Several
factors of variability, referred to as covariates in pharmacokinetic modeling, are known to …

Background: Different liquid chromatography tandem mass spectrometry (LC–MS/MS)
methods have been published for quantification of monoclonal antibodies (mAbs) in plasma …

Introduction Hepatocellular carcinoma (HCC) is the fifth malignancy in terms of frequency
and the fourth malignancy in terms of cancer-related death worldwide. Systemic therapy of …

Monoclonal antibodies (Mabs) have become key drugs in cancer treatment, either as
targeted therapies or more recently as immune checkpoint inhibitors (ICIs). The fact that only …

Therapeutic antibodies are increasingly used to treat various diseases, including neoplasms
and chronic inflammatory diseases. Antibodies exhibit complex pharmacokinetic properties …